Certican (Everolimus) for Recipients of Kidney From HLA-identical Living Donors
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Efficacy compound outcome
Incidence of treatment failure, defined as the first occurrence of biopsy confirmed acute rejection, graft loss, death, or treatment discontinuation.
Brazil: Agência Nacional de Vigilância Sanitária (ANVISA)